JP2006524699A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006524699A5 JP2006524699A5 JP2006513242A JP2006513242A JP2006524699A5 JP 2006524699 A5 JP2006524699 A5 JP 2006524699A5 JP 2006513242 A JP2006513242 A JP 2006513242A JP 2006513242 A JP2006513242 A JP 2006513242A JP 2006524699 A5 JP2006524699 A5 JP 2006524699A5
- Authority
- JP
- Japan
- Prior art keywords
- diuretic
- combination
- metabolite
- prodrug
- amide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000001882 diuretic effect Effects 0.000 claims 104
- 239000002934 diuretic Substances 0.000 claims 100
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 50
- 150000001408 amides Chemical class 0.000 claims 37
- 150000002148 esters Chemical class 0.000 claims 37
- 239000002207 metabolite Substances 0.000 claims 37
- 239000000651 prodrug Substances 0.000 claims 37
- 229940002612 prodrug Drugs 0.000 claims 37
- 150000003839 salts Chemical class 0.000 claims 37
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 28
- 239000003814 drug Substances 0.000 claims 28
- 229940109239 creatinine Drugs 0.000 claims 25
- 229940079593 drug Drugs 0.000 claims 19
- 239000003795 chemical substances by application Substances 0.000 claims 18
- 230000003907 kidney function Effects 0.000 claims 17
- 230000008327 renal blood flow Effects 0.000 claims 15
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 14
- 229960005305 adenosine Drugs 0.000 claims 14
- 239000002171 loop diuretic Substances 0.000 claims 12
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 11
- 230000001939 inductive effect Effects 0.000 claims 9
- 208000017169 kidney disease Diseases 0.000 claims 9
- 210000002966 serum Anatomy 0.000 claims 8
- 229940030606 diuretics Drugs 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- FNYLWPVRPXGIIP-UHFFFAOYSA-N Triamterene Chemical compound NC1=NC2=NC(N)=NC(N)=C2N=C1C1=CC=CC=C1 FNYLWPVRPXGIIP-UHFFFAOYSA-N 0.000 claims 5
- 229960002576 amiloride Drugs 0.000 claims 5
- LXMSZDCAJNLERA-ZHYRCANASA-N spironolactone Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CCC(=O)C=C4C[C@H]([C@@H]13)SC(=O)C)C[C@@]21CCC(=O)O1 LXMSZDCAJNLERA-ZHYRCANASA-N 0.000 claims 5
- 229960002256 spironolactone Drugs 0.000 claims 5
- 239000003451 thiazide diuretic agent Substances 0.000 claims 5
- 229960001288 triamterene Drugs 0.000 claims 5
- 208000004880 Polyuria Diseases 0.000 claims 4
- 206010061481 Renal injury Diseases 0.000 claims 4
- 230000003247 decreasing effect Effects 0.000 claims 4
- 229960003883 furosemide Drugs 0.000 claims 4
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims 4
- XSDQTOBWRPYKKA-UHFFFAOYSA-N amiloride Chemical compound NC(=N)NC(=O)C1=NC(Cl)=C(N)N=C1N XSDQTOBWRPYKKA-UHFFFAOYSA-N 0.000 claims 3
- 238000011863 diuretic therapy Methods 0.000 claims 3
- 239000012530 fluid Substances 0.000 claims 3
- 230000001434 glomerular Effects 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- UJEWTUDSLQGTOA-UHFFFAOYSA-N Piretanide Chemical compound C=1C=CC=CC=1OC=1C(S(=O)(=O)N)=CC(C(O)=O)=CC=1N1CCCC1 UJEWTUDSLQGTOA-UHFFFAOYSA-N 0.000 claims 2
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 claims 2
- -1 amiloride thiazide Chemical class 0.000 claims 2
- 229960004064 bumetanide Drugs 0.000 claims 2
- MAEIEVLCKWDQJH-UHFFFAOYSA-N bumetanide Chemical compound CCCCNC1=CC(C(O)=O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1 MAEIEVLCKWDQJH-UHFFFAOYSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 230000035619 diuresis Effects 0.000 claims 2
- AVOLMBLBETYQHX-UHFFFAOYSA-N etacrynic acid Chemical compound CCC(=C)C(=O)C1=CC=C(OCC(O)=O)C(Cl)=C1Cl AVOLMBLBETYQHX-UHFFFAOYSA-N 0.000 claims 2
- 229960003199 etacrynic acid Drugs 0.000 claims 2
- 229960001085 piretanide Drugs 0.000 claims 2
- 229960005461 torasemide Drugs 0.000 claims 2
- 206010016803 Fluid overload Diseases 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000035433 tubuloglomerular feedback Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46600703P | 2003-04-25 | 2003-04-25 | |
| PCT/US2004/012518 WO2004096228A1 (en) | 2003-04-25 | 2004-04-23 | Method of improved diuresis in individuals with impaired renal function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006524699A JP2006524699A (ja) | 2006-11-02 |
| JP2006524699A5 true JP2006524699A5 (OSRAM) | 2006-12-14 |
Family
ID=33418325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006513242A Withdrawn JP2006524699A (ja) | 2003-04-25 | 2004-04-23 | 腎機能障害を持つ個体における利尿改善法 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US7579331B2 (OSRAM) |
| EP (1) | EP1620107A1 (OSRAM) |
| JP (1) | JP2006524699A (OSRAM) |
| KR (1) | KR20060004959A (OSRAM) |
| CN (1) | CN1859913A (OSRAM) |
| AR (1) | AR044069A1 (OSRAM) |
| AU (1) | AU2004233852A1 (OSRAM) |
| BR (1) | BRPI0409699A (OSRAM) |
| CA (1) | CA2522971A1 (OSRAM) |
| MX (1) | MXPA05011371A (OSRAM) |
| NO (1) | NO20055536L (OSRAM) |
| NZ (1) | NZ543109A (OSRAM) |
| RU (1) | RU2367442C2 (OSRAM) |
| TW (1) | TW200500070A (OSRAM) |
| WO (1) | WO2004096228A1 (OSRAM) |
| ZA (1) | ZA200509311B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040229901A1 (en) * | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| AU2004233852A1 (en) | 2003-04-25 | 2004-11-11 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
| US20060293312A1 (en) * | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
| JP2007504136A (ja) * | 2003-08-28 | 2007-03-01 | ニトロメッド インコーポレーティッド | ニトロソ化およびニトロシル化利尿化合物、組成物、ならびに使用方法 |
| JP2007532671A (ja) * | 2004-04-16 | 2007-11-15 | ノヴァカーディア，インク． | アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法 |
| WO2006091716A2 (en) * | 2005-02-24 | 2006-08-31 | Nitromed, Inc. | Nitric oxide enhancing diuretic compounds, compositions and methods of use |
| CN101166515A (zh) * | 2005-04-22 | 2008-04-23 | 美国诺华卡迪亚公司 | 用于非水溶性药物成分静脉注射的乳剂的生产 |
| JPWO2007069675A1 (ja) * | 2005-12-14 | 2009-05-28 | 協和発酵キリン株式会社 | キサンチン誘導体の易吸収性経口製剤 |
| CA2648281A1 (en) * | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine a1 receptor antagonists and anticonvulsants |
| EP2035009A1 (en) * | 2006-06-16 | 2009-03-18 | Novacardia, Inc. | Prolonged improvement of renal function comprising infrequent administration of an aa1ra |
| WO2007149283A2 (en) * | 2006-06-16 | 2007-12-27 | Novacardia, Inc. | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| WO2008121882A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Improved methods of administration of adenosine a1 receptor antagonists |
| WO2008121893A1 (en) * | 2007-03-29 | 2008-10-09 | Novacardia, Inc. | Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE416810C (sv) | 1977-10-14 | 1982-07-19 | Draco Ab | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet |
| FR2531085A1 (fr) | 1982-07-28 | 1984-02-03 | Adir | Nouveaux derives de la xanthine, leur procede de preparation et les compositions pharmaceutiques les renfermant |
| US4769377A (en) | 1983-02-18 | 1988-09-06 | The Johns Hopkins University | Adenosine receptor antagonists |
| DE8817122U1 (de) | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5290782A (en) | 1989-09-01 | 1994-03-01 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives |
| SE9000207L (sv) | 1990-01-22 | 1991-07-23 | Nobel Chemicals Ab | Laekemedel samt anvaendningen av detsamma |
| DE4019892A1 (de) | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| WO1993000081A1 (en) | 1991-06-28 | 1993-01-07 | Sepracor, Inc. | Optically pure s(-) nadolol for treatment of cardiovascular disorders |
| CA2093403C (en) | 1992-04-08 | 1999-08-10 | Fumio Suzuki | Therapeutic agent for parkinson's disease |
| TW252044B (OSRAM) | 1992-08-10 | 1995-07-21 | Boehringer Ingelheim Kg | |
| DE4238367A1 (de) | 1992-11-13 | 1994-05-19 | Boehringer Ingelheim Kg | Diuretisches Mittel |
| US5395836A (en) | 1993-04-07 | 1995-03-07 | Kyowa Hakko Kogyo Co., Ltd. | 8-tricycloalkyl xanthine derivatives |
| US5446046A (en) | 1993-10-28 | 1995-08-29 | University Of Florida Research Foundation | A1 adenosine receptor agonists and antagonists as diuretics |
| US5736528A (en) | 1993-10-28 | 1998-04-07 | University Of Florida Research Foundation, Inc. | N6 -(epoxynorborn-2-yl) adenosines as A1 adenosine receptor agonists |
| CN1049117C (zh) | 1994-09-16 | 2000-02-09 | 赵明玉 | 预防和治疗偏头痛的偏头痛片 |
| WO1997004782A1 (en) | 1995-07-26 | 1997-02-13 | Kyowa Hakko Kogyo Co., Ltd. | Solid dispersion or solid dispersion preparation of xanthine derivatives |
| ES2232877T3 (es) | 1996-08-07 | 2005-06-01 | Kyowa Hakko Kogyo Co., Ltd. | Emulsion grasa que contiene un derivado de xantina. |
| US6187780B1 (en) | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
| DE19816857A1 (de) | 1998-04-16 | 1999-10-21 | Boehringer Ingelheim Pharma | Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| US20020115687A1 (en) | 1998-04-24 | 2002-08-22 | Evan Beckman | Method and composition for restoring diuretic and renal function |
| AU3757999A (en) | 1998-04-24 | 1999-11-16 | Biogen, Inc. | Adenosine a1 receptor antagonist containing composition and method for restoringdiuretic and renal function |
| EP0970696A1 (en) * | 1998-05-05 | 2000-01-12 | Kyowa Hakko Kogyo Co., Ltd. | Combination of loop diuretics with adenosine A1-receptor antagonists |
| UA74141C2 (uk) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| CA2390496A1 (en) | 1999-11-12 | 2001-05-17 | Biogen, Inc. | Polycycloalkylpurines as adenosine receptor antagonists |
| PL198156B1 (pl) | 1999-11-12 | 2008-05-30 | Biogen Idec Ma | Ksantyny podstawione w pozycji 8, sposób ich wytwarzania i ich zastosowanie oraz kompozycja farmaceutyczna |
| US20050038017A1 (en) | 1999-12-22 | 2005-02-17 | Wolff Andrew A. | Method and composition for restoring diuretic and renal function |
| UA75625C2 (en) | 2000-12-01 | 2006-05-15 | Biogen Inc | Condensed purine derivatives as a1 adenosine receptor antagonists |
| MXPA03005462A (es) | 2000-12-18 | 2003-09-25 | Novartis Ag | Combinacion terapeutica de amlodipina y benazepril. |
| UA80258C2 (en) | 2001-09-06 | 2007-09-10 | Biogen Inc | Methods of treating pulmonary disease |
| US20040229901A1 (en) | 2003-02-24 | 2004-11-18 | Lauren Otsuki | Method of treatment of disease using an adenosine A1 receptor antagonist |
| AU2004233852A1 (en) | 2003-04-25 | 2004-11-11 | Novacardia, Inc. | Method of improved diuresis in individuals with impaired renal function |
| US20060293312A1 (en) | 2003-04-25 | 2006-12-28 | Howard Dittrich | Method of improved diuresis in individuals with impaired renal function |
| US20050070524A1 (en) | 2003-06-06 | 2005-03-31 | Pharmacia Corporation | Compositions of a cyclooxygenase-2 selective inhibitor and an anticonvulsant agent for the treatment of central nervous system disorders |
| JP2007532671A (ja) | 2004-04-16 | 2007-11-15 | ノヴァカーディア，インク． | アデノシンａ１受容体アンタゴニストおよびアルドステロン阻害剤を含む併用療法 |
| CA2565037A1 (en) | 2004-04-28 | 2005-11-10 | Cv Therapeutics, Inc. | Purine derivatives as a1 adenosine receptor antagonists |
| CA2648281A1 (en) | 2006-04-06 | 2007-10-18 | Novacardia, Inc. | Co-administration of adenosine a1 receptor antagonists and anticonvulsants |
| EP2035009A1 (en) | 2006-06-16 | 2009-03-18 | Novacardia, Inc. | Prolonged improvement of renal function comprising infrequent administration of an aa1ra |
| WO2007149283A2 (en) | 2006-06-16 | 2007-12-27 | Novacardia, Inc. | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload |
| CA2661044A1 (en) | 2006-08-22 | 2008-02-28 | Novacardia, Inc. | Kw-3902 conjugates that do not cross the blood-brain barrier |
-
2004
- 2004-04-23 AU AU2004233852A patent/AU2004233852A1/en not_active Abandoned
- 2004-04-23 RU RU2005131938/15A patent/RU2367442C2/ru not_active IP Right Cessation
- 2004-04-23 NZ NZ543109A patent/NZ543109A/en unknown
- 2004-04-23 WO PCT/US2004/012518 patent/WO2004096228A1/en not_active Ceased
- 2004-04-23 EP EP04760339A patent/EP1620107A1/en not_active Withdrawn
- 2004-04-23 CA CA002522971A patent/CA2522971A1/en not_active Abandoned
- 2004-04-23 JP JP2006513242A patent/JP2006524699A/ja not_active Withdrawn
- 2004-04-23 AR ARP040101381A patent/AR044069A1/es unknown
- 2004-04-23 CN CNA2004800105597A patent/CN1859913A/zh active Pending
- 2004-04-23 BR BRPI0409699-1A patent/BRPI0409699A/pt not_active IP Right Cessation
- 2004-04-23 US US10/830,617 patent/US7579331B2/en not_active Expired - Fee Related
- 2004-04-23 TW TW093111522A patent/TW200500070A/zh unknown
- 2004-04-23 KR KR1020057020243A patent/KR20060004959A/ko not_active Ceased
- 2004-04-23 MX MXPA05011371A patent/MXPA05011371A/es not_active Application Discontinuation
-
2005
- 2005-10-11 US US11/248,905 patent/US20060035911A1/en not_active Abandoned
- 2005-10-11 US US11/248,479 patent/US20060030572A1/en not_active Abandoned
- 2005-11-17 ZA ZA200509311A patent/ZA200509311B/en unknown
- 2005-11-23 NO NO20055536A patent/NO20055536L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Fogel et al. | Diuresis in the ascitic patient: a randomized controlled trial of three regimens | |
| JP2020508339A5 (OSRAM) | ||
| JP6353577B2 (ja) | 組み合わせ組成物 | |
| JP2002522485A5 (OSRAM) | ||
| HRP20210294T1 (hr) | Postupci liječenja akutnog bubrežnog oštećenja | |
| JP2002528502A5 (OSRAM) | ||
| Cruz et al. | Intradialytic hypotension: Is midodrine beneficial in symptomatic hemodialysis patients? | |
| JP2019533660A5 (OSRAM) | ||
| JP2018531929A5 (OSRAM) | ||
| JP2017514911A5 (OSRAM) | ||
| HRP20221185T1 (hr) | Beta-ukosnica peptidomimetik s inhibitorskom aktivnošću elastase i njegovi oblici doziranja aerosolom | |
| WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
| EP1435968A1 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
| Achong et al. | Fatal self-poisoning with lithium carbonate | |
| CN110974828A (zh) | 化合物Axitinib在制备治疗脑血管疾病的药物中的应用及其药物组合物 | |
| RU2005131938A (ru) | Способ нормализации мочеиспускания при нарушении функции почек | |
| Knowles et al. | Pityriasis rubra pilaris: prolonged treatment with methotrexate | |
| Mir et al. | Reversal of cardiovascular toxicity in severe organophosphate poisoning with 20% Intralipid emulsion therapy: case report and review of literature | |
| JP2019509309A5 (OSRAM) | ||
| RS64668B1 (sr) | Montelukast za lečenje erozivnog osteoartritisa šake | |
| Nanji et al. | Lactulose-induced hypernatremia | |
| JP2009506088A (ja) | チアジド系利尿薬とループ利尿薬との組合せ調製物 | |
| RU2005131943A (ru) | Лечебные и/или профилактические средства для хронических болезней кожи | |
| Ramanathan | Pharmacology review: bronchopulmonary dysplasia and diuretics | |
| Roberts et al. | Diuretics |